ClinicalTrials.gg
RecruitingNCT06764771Updated Jul 29, 2026

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

A Phase 1 interventional study of BMS-986488 and Adagrasib in Advanced Malignant Tumors, sponsored by Bristol-Myers Squibb. Recruiting at 8 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.

Primary conditionNeoplasms(registry's first term: Colorectal Neoplasms)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Colorectal Neoplasms, so we do not take that as its main condition. It is compared within Neoplasms.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

How we know · 13 judgments

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
437
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.

02

Conditions studied

  • Advanced Malignant Tumors

Browse trials for

Keywords

  • Colorectal Cancer
  • CRC
  • Renal Cell Carcinoma
  • RCC
  • Non-Small Cell Lung Cancer
  • NSCLC
  • Cancer
  • Oncology
  • Phase 1
  • Solid Tumor
03

In context

Neoplasms Many cancers

10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's planned enrollment of 437 is above the median of 60 across 7,714 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Compared within Neoplasms: the study is open to many cancers; the registry's first condition term is Colorectal Neoplasms. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥ 18 years of age.
  • confirmed diagnosis of a locally advanced and unresectable or solid tumor with any of the following tumor types:.
  • Part 1A: clear-cell renal cell carcinoma (ccRCC), clear-cell ovarian cancer (ccOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC).
  • Parts 2A, 1D, 2D: ccRCC.

    i) Part 1B: solid tumors with KRAS G12C mutation.

ii) Part 2B: NSCLC with KRAS G12C mutation.

iii) Parts 1C, 2C: colorectal cancer (CRC) with KRAS G12C mutation.

  • Participants must have an Eastern Cooperative Oncology Groups () Performance Status of 0 or 1.
  • Participants must have per v1.1.

Exclusion criteria

Exclusion Criteria:

  • Untreated central nervous system (CNS) .
  • (carcinomatous meningitis).
  • Impaired cardiac function or cardiac disease.
  • For Parts 1B, 1C, 2B, 2C only (combination with adagrasib):.

    i) History of pneumonitis or interstitial lung disease (ILD).

ii) History of prior severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

- Other protocol-defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
437 participants (estimated)

Study arms

  • Experimental
    Part 1A: BMS-986488 Monotherapy

    Drug: BMS-986488

  • Experimental
    Part 1B: BMS-986488 + Adagrasib

    Drug: BMS-986488 · Drug: Adagrasib

  • Experimental
    Part 1C: BMS-986488 + Adagrasib + Cetuximab

    Drug: BMS-986488 · Drug: Adagrasib · Drug: Cetuximab

  • Experimental
    Part 1D: BMS-986488 + Nivolumab

    Drug: BMS-986488 · Drug: Nivolumab

  • Experimental
    Part 2A: BMS-986488 Monotherapy

    Drug: BMS-986488

  • Experimental
    Part 2B: BMS-986488 + Adagrasib

    Drug: BMS-986488 · Drug: Adagrasib

  • Experimental
    Part 2C: BMS-986488 + Adagrasib + Cetuximab

    Drug: BMS-986488 · Drug: Adagrasib · Drug: Cetuximab

  • Experimental
    Part 2D: BMS-986488 + Nivolumab

    Drug: BMS-986488 · Drug: Nivolumab

Interventions

  • DrugBMS-986488

    Specified dose on specified days

  • Specified dose on specified days

    Also known as: KRAZATI, BMS-986503, MRTX849

  • Specified dose on specified days

    Also known as: ERBITUX

  • Specified dose on specified days

    Also known as: OPDIVO, BMS-936558

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse Events (AEs)

    Time frame: Until the end of the Safety Follow-up period (up to approximately 100 days after last dose)

  2. Number of participants with Serious AEs (SAEs)

    Time frame: Until the end of the Safety Follow-up period (up to approximately 100 days after last dose)

  3. Number of participants with AEs meeting protocol-defined Dose-Limiting Toxicity (DLT) criteria

    Time frame: From first dose of study treatment until end of cycle 1 (1 Cycle = 28 Days)

  4. Number of participants with AEs leading to discontinuation

    Time frame: Until the end of the Safety Follow-up period (up to approximately 100 days after last dose)

  5. Number of deaths

    Time frame: From time of informed consent up to 52 weeks after end of treatment visit

Secondary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Until Cycle 4, Day 1 (1 Cycle = 28 Days)

  2. Time of maximum observed concentration (Tmax)

    Time frame: Until Cycle 4, Day 1 (1 Cycle = 28 Days)

  3. Area under the concentration-time curve in 1 dosing interval (AUC(TAU))

    Time frame: Until Cycle 4, Day 1 (1 Cycle = 28 Days)

  4. Objective response rate (ORR)

    Defined as the proportion of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR) assessed by the investigator using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)

    Time frame: From time of informed consent up to 52 weeks after end of treatment visit

  5. Disease control rate (DCR)

    Defined as the proportion of participants who achieve a best response of CR, PR, or stable disease (SD) assessed by the investigator using RECIST v1.1

    Time frame: From time of informed consent up to 52 weeks after end of treatment visit

  6. Duration of response (DOR)

    Defined as the time between the date of first documented response (CR or PR) to the date of the first documented disease progression as assessed by the investigator using RECIST v1.1 or death due to any cause, whichever occurs first

    Time frame: From time of informed consent up to 52 weeks after end of treatment visit

07

Study locations

4 of 8 sites recruiting
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
    Recruiting
    • Martin Gutierrez, Site 0021 · Contact551-996-5863
  • Local Institution - 0020
    Allentown, Pennsylvania 18103, United States
    Active, not recruiting

    Not enrolling at this site.

  • The West Clinic, PLLC dba West Cancer Center
    Germantown, Tennessee 38138, United States
    Recruiting
    • Daniel Vaena, Site 0024 · Contact901-598-1454
  • Local Institution - 0025
    Dallas, Texas 75390, United States
    Withdrawn

    Not enrolling at this site.

  • Local Institution - 0031
    Brisbane, Queensland 4029, Australia
    Active, not recruiting

    Not enrolling at this site.

  • BC Cancer Vancouver
    Vancouver, British Columbia V5Z 4E6, Canada
    Recruiting
    • Christian Kollmannsberger, Site 0032 · Contact6048776000
  • Local Institution - 0015
    Montreal, Quebec H2X 0A9, Canada
    Not yet recruiting
    • Site 0015 · Contact
  • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus
    Québec, Quebec G1J 1Z4, Canada
    Recruiting
    • Antoine Morin Coulombe, Site 0016 · Contact4185254444
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Oct 2027, 30 months after the start.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's planned 30 months is below that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2025
First posted
Jan 8, 2025
StartActual
Mar 25, 2025
Primary completionEst.
Oct 15, 2027
CompletionEst.
Oct 15, 2027
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06764771
Responsible party
Sponsor
First posted
Jan 8, 2025
Start date
Mar 25, 2025
Primary completion
Oct 15, 2027 (estimated)
Completion
Oct 15, 2027 (estimated)
Last update
Jul 29, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion